



## Evusheld Fact Sheet

Evusheld is a long-acting monoclonal antibody combination that has received Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the pre-exposure prophylaxis of COVID-19 in individuals 12 years of age and older who:

- Are moderately to severely immune-compromised due to a medical condition, or who have received immunosuppressive medications or treatments, and may not mount an adequate immune response to COVID-19 vaccination
- Are not recommended to receive COVID-19 vaccination due to a history of vaccine adverse reaction to a COVID-19 vaccine and/or COVID-19 vaccine component.

FDA has revised the EUA for Evusheld, increasing the authorized dosage to 300 mg of tixagevimab and 300 mg of cilgavimab. Patients who may have already received the original authorized dose of 150 mg tixagevimab and 150 mg of cilgavimab should now receive an additional dose of 150 mg tixagevimab and 150 mg of cilgavimab as soon as possible to raise their monoclonal antibody levels to those that are expected with the higher dose.

Evusheld is administered as two separate consecutive intramuscular injections, and maybe repeated every six months while COVID-19 remains in circulation. The Injections should be given in large muscle sites, such as the gluteal muscles.

Health care professionals should review the Emergency Use Authorization and Fact Sheets for Evusheld ([Evusheld Patients, Parents, and Caregivers FS 02242022 \(fda.gov\)](#))

The FDA requires all health care providers who prescribe Evusheld to report all medication errors and serious adverse events through the FDA's MedWatch Adverse Event Reporting Program ([Prevention of SARS-CoV-2 | COVID-19 Treatment Guidelines \(nih.gov\)](#))

Pima County Health Department has partnered with FEMA and Carondelet St. Raphael's Emergency Center to provide Evusheld with a physician referral. Physicians may refer a patient by calling 520-872-1801 or faxing the referral form attached to 520-493-0470.

**A Healthy Pima County**  
Every one. Every where. Every day.